1
ALL1
Juvise PharmaceuticalsYear
1
ALL1
2022DEALS // DEV.
1
ALL1
DealsCountry
1
ALL1
FRANCE1
ALL1
AbbVie IncTherapeutic Area
1
ALL1
Infections and Infectious DiseasesStudy Phase
1
ALL1
Approved FDFDeal Type
1
ALL1
AcquisitionProduct Type
1
ALL1
Other Small MoleculeDosage Form
1
ALL1
Oral CapsuleLead Product
1
ALL1
Bismuth Potassium CitrateTarget
1
ALL1
Bacterial cell wall synthesisLead Product(s) : Bismuth Potassium Citrate,Metronidazole
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : AbbVie Inc
Deal Size : Undisclosed
Deal Type : Acquisition
Details : Pylera®, a 3-in-1 combination of antimicrobial products, is indicated for the treatment of patients with Helicobacter pylori infection suffering from gastro-duodenal ulcer disease.
Product Name : Pylera
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
May 07, 2022
Lead Product(s) : Bismuth Potassium Citrate,Metronidazole
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : AbbVie Inc
Deal Size : Undisclosed
Deal Type : Acquisition